Liver-selective expression of human arylamine N-acetyltransferase NAT2 in transgenic mice

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 882-890

  Sugamori, Kim S ^a   Brenneman, Debbie ^a   Grant, Denis M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 BIPHENYLAMINE; AMINOSALICYLIC ACID; ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE N ACETYLTRANSFERASE 2; SULFADIMIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; GENE EXPRESSION; LIVER; LIVER CYTOSOL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SPECIES DIFFERENCE; TRANSGENIC MOUSE; WILD TYPE;

AMINOSALICYLIC ACID; ANIMALS; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CYTOSOL; FEMALE; GENOTYPE; HUMANS; LIVER; MALE; MICE; MICE, TRANSGENIC; SULFAMETHAZINE;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 79955036094     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.038216     Document Type: Article

References (46)

1. Bendaly J, Doll MA, Millner LM, Metry KJ, Smith NB, Pierce WM Jr, and Hein DW (2009) Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenylinduced DNA adducts and mutations. Mutat Res 671:13-19.
2. Cao W, Chau B, Hunter R, Strnatka D, McQueen CA, and Erickson RP (2005) Only low levels of exogenous N-acetyltransferase can be achieved in transgenic mice. Pharmacogenomics J 5:255-261. (Pubitemid 41131717)
3. Cao W, Strnatka D, McQueen CA, Hunter RJ, and Erickson RP (2010) N-Acetyltransferase 2 activity and folate levels. Life Sci 86:103-106.
4. Chapron DJ, Kramer PA, and Mercik SA (1980) Kinetic discrimination of three sulfamethazine acetylation phenotypes. Clin Pharmacol Ther 27:104-113. (Pubitemid 10128549)
5. Cheung C and Gonzalez FJ (2008) Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 327: 288-299.
6. Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, Dalton TP, Nebert DW, Idle JR, and Gonzalez FJ (2005) Differential metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 18:1471-1478. (Pubitemid 41361721)
7. Dairou J, Atmane N, Rodrigues-Lima F, and Dupret JM (2004) Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: A cellular and mechanistic study. J Biol Chem 279: 7708-7714. (Pubitemid 38294653)
8. Dairou J, Petit E, Ragunathan N, Baeza-Squiban A, Marano F, Dupret JM, and Rodrigues-Lima F (2009) Arylamine N-acetyltransferase activity in bronchial epithelial cells and its inhibition by cellular oxidants. Toxicol Appl Pharmacol 236:366-371.
9. Doll MA, Zang Y, Moeller T, and Hein DW (2010) Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes. J Pharmacol Exp Ther 334:540-544.
10. Dragin N, Uno S, Wang B, Dalton TP, and Nebert DW (2007) Generation of 'humanized' hCYP1A1-1A2-Cyp1a1/1a2(-/-) mouse line. Biochem Biophys Res Commun 359:635-642. (Pubitemid 46898998)
11. Ferguson RJ, Doll MA, Rustan TD, Gray K, and Hein DW (1994) Cloning, expression, and functional characterization of two mutant (NAT2191 and NAT2341/803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metab Dispos 22:371-376. (Pubitemid 24158534)
12. Flammang TJ, Tungeln LS, Kadlubar FF, and Fu PP (1997) Neonatal mouse assay for tumorigenicity: Alternative to the chronic rodent bioassay. Regul Toxicol Pharmacol 26:230-240. (Pubitemid 27494297)
13. Glowinski IB and Weber WW (1982) Genetic regulation of aromatic amine N-acetylation in inbred mice. J Biol Chem 257:1424-1430. (Pubitemid 12121652)
14. Grant DM, Blum M, Beer M, and Meyer UA (1991) Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184-191.
15. Hein D (2002) Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat Res 506-507:65-77. (Pubitemid 35286541)
16. Hein DW (2006) N-Acetyltransferase 2 genetic polymorphism: Effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25:1649-1658.
17. Hein DW (2009) N-Acetyltransferase SNPs: Emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol 5:353-366.
18. Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, Payton M, Unadkat JD, and Sim E (1998) Expression of arylamine N-acetyltransferase in human intestine. Gut 42:402-409. (Pubitemid 28197032)
19. Husain A, Zhang X, Doll MA, States JC, Barker DF, and Hein DW (2007) Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 35:721-727. (Pubitemid 46641541)
20. Kawamura A, Westwood I, Wakefield L, Long H, Zhang N, Walters K, Redfield C, and Sim E (2008) Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1. Biochem Pharmacol 75:1550-1560.
21. Kim D and Guengerich FP (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol 45:27-49. (Pubitemid 40261797)
22. Kimura S, Kawabe M, Ward JM, Morishima H, Kadlubar FF, Hammons GJ, Fernandez-Salguero P, and Gonzalez FJ (1999) CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl- induced hepatocarcinogenesis in mice. Carcinogenesis 20:1825-1830. (Pubitemid 29410564)
23. Kimura S, Kawabe M, Yu A, Morishima H, Fernandez-Salguero P, Hammons GJ, Ward JM, Kadlubar FF, and Gonzalez FJ (2003) Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. Carcinogenesis 24:583-587. (Pubitemid 36432656)
24. Lakics V, Karran EH, and Boess FG (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:367-374.
25. Lambert IB, Singer TM, Boucher SE, and Douglas GR (2005) Detailed review of transgenic rodent mutation assays. Mutat Res 590:1-280. (Pubitemid 41121981)
26. Leff MA, Epstein PN, Doll MA, Fretland AJ, Devanaboyina US, Rustan TD, and Hein DW (1999) Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J Pharmacol Exp Ther 290:182-187. (Pubitemid 29302318)
27. Loehle JA, Cornish V, Wakefield L, Doll MA, Neale JR, Zang Y, Sim E, and Hein DW (2006) N-Acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice. J Pharmacol Exp Ther 319:724-728.
28. Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR, Johnson AT, Lubin JH, Hein DW, Dagnall CL, et al. (2011) GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: Results from the New England Bladder Cancer Study and NAT2 meta-analysis. Carcinogenesis 32:182-189.
29. Nebert DW and Dalton TP (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947-960. (Pubitemid 44862679)
30. Neumann HG (2007) Aromatic amines in experimental cancer research: Tissue-specific effects, an old problem and new solutions. Crit Rev Toxicol 37:211-236.
31. Nöthlings U, Yamamoto JF, Wilkens LR, Murphy SP, Park SY, Henderson BE, Kolonel LN, and Le Marchand L (2009) Meat and heterocyclic amine intake, smoking, NAT1 and NAT2 polymorphisms, and colorectal cancer risk in the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 18:2098-2106.
32. Omori K and Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100:309-327.
33. Pinkert CA, Ornitz DM, Brinster RL, and Palmiter RD (1987) An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev 1:268-276.
34. Rabstein S, Brüning T, Harth V, Fischer HP, Haas S, Weiss T, Spickenheuer A, Pierl C, Justenhoven C, Illig T, et al. (2010) N-Acetyltransferase 2, exposure to aromatic and heterocyclic amines, and receptor-defined breast cancer. Eur J Cancer Prev 19:100-109.
35. Sharma S, Cao X, Wilkens LR, Yamamoto J, Lum-Jones A, Henderson BE, Kolonel LN, and Le Marchand L (2010) Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: The multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 19:1866-1870.
36. Sim E, Lack N, Wang CJ, Long H, Westwood I, Fullam E, and Kawamura A (2008) Arylamine N-acetyltransferases: Structural and functional implications of polymorphisms. Toxicology 254:170-183.
37. Smolen TN, Brewer JA, and Weber WW (1993) Testosterone modulation of N-acetylation in mouse kidney. J Pharmacol Exp Ther 264:854-858. (Pubitemid 24283550)
38. Stabbert R, Schäfer KH, Biefel C, and Rustemeier K (2003) Analysis of aromatic amines in cigarette smoke. Rapid Commun Mass Spectrom 17:2125-2132. (Pubitemid 37098328)
39. Sugamori KS, Brenneman D, and Grant DM (2006) In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice. Drug Metab Dispos 34:1697-1702. (Pubitemid 44427472)
40. Sugamori KS, Brenneman D, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, and Grant DM (2007) Effect of arylamine acetyltransferase Nat3 gene knockout on N-acetylation in the mouse. Drug Metab Dispos 35:1064-1070. (Pubitemid 46956425)
41. Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, and Grant DM (2003) Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double- knockout mice. Mol Pharmacol 64:170-179. (Pubitemid 36759829)
42. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, et al. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912. (Pubitemid 39129297)
43. Tsuneoka Y, Dalton TP, Miller ML, Clay CD, Shertzer HG, Talaska G, Medvedovic M, and Nebert DW (2003) 4-Aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(-/-) mice. J Natl Cancer Inst 95:1227-1237. (Pubitemid 37069553)
44. Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, and Nebert DW (2004) Oral exposure to benzo[a]pyrene in the mouse: Detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 65:1225-1237. (Pubitemid 38543493)
45. Wang AG, Moon HB, Lee MR, Hwang CY, Kwon KS, Yu SL, Kim YS, Kim M, Kim JM, Kim SK, et al. (2005) Gender-dependent hepatic alterations in H-ras12V transgenic mice. J Hepatol 43:836-844. (Pubitemid 41414510)
46. Weisburger J (2002) Comments on the history and importance of aromatic and heterocyclic amines in public health. Mutat Res 506-507:9-20. (Pubitemid 35291144)